Stay updated on Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record of a clinical research study aiming to find the highest tolerable dose of PROHIBITIN-TP01 for patients with advanced prostate cancer and obesity, as well as studying the safety of the drug.
    Difference
    0.1%
    Check dated 2024-06-06T14:16:13.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals with metastatic or incurable prostate cancer and a BMI classified as obese. The criteria also outline specific health conditions and prior treatments required for participation.
    Difference
    34%
    Check dated 2024-05-22T19:25:54.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map'. This change likely indicates a shift in the type of intervention or content being featured on the webpage, possibly related to medical and healthcare publications and documentation.
    Difference
    0.8%
    Check dated 2024-05-01T17:35:54.000Z thumbnail image

Stay in the know with updates to Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page.